Novartis AG
NVS · NYSE
9/29/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $3,930,000 | $4,024,000 | $3,606,000 | $2,818,000 |
| Dep. & Amort. | $1,364,000 | $1,256,000 | $1,150,000 | $1,628,000 |
| Deferred Tax | $266,000 | $507,000 | $798,000 | $465,000 |
| Stock-Based Comp. | $268,000 | $267,000 | $262,000 | $272,000 |
| Change in WC | $1,336,000 | $442,000 | -$1,768,000 | $5,000 |
| Other Non-Cash | -$593,000 | $168,000 | -$403,000 | -$995,000 |
| Operating Cash Flow | $6,571,000 | $6,664,000 | $3,645,000 | $4,193,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$354,000 | -$331,000 | -$254,000 | -$558,000 |
| Net Acquisitions | -$160,000 | -$1,678,000 | $6,000 | -$264,000 |
| Inv. Purchases | -$100,000 | -$58,000 | -$55,000 | -$2,305,000 |
| Inv. Sales/Matur. | $179,000 | $50,000 | $1,876,000 | $581,000 |
| Other Inv. Act. | -$425,000 | -$226,000 | -$1,243,000 | -$487,000 |
| Investing Cash Flow | -$860,000 | -$2,243,000 | $330,000 | -$3,033,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$511,000 | $181,000 | -$523,000 | -$106,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$2,302,000 | -$2,714,000 | -$2,716,000 | -$2,762,000 |
| Dividends Paid | $0 | -$2,485,000 | -$5,333,000 | $0 |
| Other Fin. Act. | $24,000 | -$195,000 | $24,000 | -$128,000 |
| Financing Cash Flow | -$2,789,000 | -$5,213,000 | -$8,548,000 | -$2,996,000 |
| Forex Effect | -$22,000 | $382,000 | $180,000 | -$314,000 |
| Net Chg. in Cash | $2,900,000 | -$410,000 | -$4,393,000 | -$2,150,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $6,656,000 | $7,066,000 | $11,459,000 | $13,609,000 |
| End Cash | $9,556,000 | $6,656,000 | $7,066,000 | $11,459,000 |
| Free Cash Flow | $5,740,000 | $6,106,000 | $2,151,000 | $3,062,000 |